IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A transdermal delivery system (TDS) comprising

a self-adhesive matrix containing a self-adhesive polymer and microreservoirs containing an amine-functional drug **in free base form** selected from the group consisting of fentanyl and oxybutynin,

wherein the microreservoirs are within the self-adhesive matrix and have a maximum diameter less than the thickness of the self-adhesive matrix; and

wherein the self-adhesive matrix is permeable to the amine-functional drug in free base form, and the self-adhesive matrix is substantially impermeable to the amine functional drug in protonated form.

2. (Previously presented) The TDS of claim 1, wherein the mean diameter of the microreservoirs is in the range of 0.5 to 20 μm.

3-9. (Cancelled)

10. (Previously presented) The TDS of claim 1, wherein the self-adhesive matrix is free of silica particles that can absorb salts of the amine functional drug at the TDS/skin interface.

11. (Previously Presented) The TDS of claim 1, wherein the self-adhesive matrix comprises a silicone pressure sensitive adhesive.

12. (Previously Presented) The TDS of claim 1, wherein the self-adhesive matrix comprises two or more silicone pressure sensitive adhesives.

13. (Previously presented) The TDS of claim 12, wherein the silicone pressure sensitive adhesive is a blend of a high tack silicone pressure sensitive adhesive comprising polysiloxane with a resin and a medium tack silicone pressure sensitive adhesive comprising polysiloxane with a resin.

14. (Cancelled)

15. (Previously presented) The TDS of claim 1, wherein the microreservoirs further contain at least one crystallization inhibitor comprising soluble polyvinylpyrrolidone, a copolymer of polyvinylpyrrolidone and vinyl acetate, polyethylene glycol, polypropylene glycol, glycerol, a fatty acid ester of glycerol and/or a copolymer of ethylene and vinyl acetate.

16. (Previously presented) The TDS of claim 15, wherein the at least one crystallization inhibitor comprises soluble polyvinylpyrrolidone.

17. (Previously presented) The TDS of claim 1, wherein the self-adhesive matrix contains 10^3 to 10^9 microreservoirs per cm^2 of the surface of the matrix.

18. (Previously presented) The TDS of claim 1, wherein the maximum diameter of the microreservoirs is not greater than 35 μm.

19. (Previously presented) The TDS of claim 1, further comprising a protective foil or sheet to be removed prior to use.

20. (Previously presented) The TDS of claim 1, further comprising a backing layer.

21. (Previously presented) The TDS of claim 20, wherein the backing layer is inert to the components of the matrix.

22. (Previously presented) The TDS of claim 1, wherein the self-adhesive matrix comprises a solid or semisolid semi-permeable polymer.

23. (Previously presented) The TDS of claim 1, wherein the self-adhesive matrix contains 10^6 to 10^9 microreservoirs per cm^2 of the surface of the matrix.

24. (Previously presented) The TDS of claim 1, further comprising a backing layer being inert to the component of the matrix, and a protective foil or sheet to be removed prior to use,

wherein the matrix contains 10^3 to 10^9 microreservoirs per cm^2 of the surface of the matrix, and wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix and is not greater than 35 μm.

25. (Currently amended) A transdermal delivery system (TDS) comprising a self-adhesive matrix containing a self-adhesive polymer and microreservoirs containing an amine-functional drug **in free base** form selected from **the group consisting of** **[[an]]** aminotetralin ~~**compound**~~ **compounds**,

wherein the microreservoirs are within the self-adhesive matrix and have a maximum diameter less than the thickness of the self-adhesive matrix; and

wherein the self-adhesive matrix is permeable to the amine-functional drug in free base form, and the self-adhesive matrix is substantially impermeable to the amine functional drug in protonated form.